[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341960-105":59,"doc-detail-341960-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","clinical-cell-surface-targets-in-metastatic-and-primary-solid-cancers","Clinical cell-surface targets in metastatic and primary solid cancers","","Therapies against cell-surface targets (CSTs) are an emerging treatment approach in solid malignancies, but large-scale CST-expression profiling has often focused on primarily non-metastatic data. This study identifies 818 clinical trials covering 78 CSTs and builds a multi-cohort expression resource using RNA-seq/microarrays across benign, primary tumor, and metastatic tumor samples. Using single-cell RNA-seq, paired RNA–protein analyses, and matched cell lines, it models RNA–protein concordance, contrasts metastatic versus primary patterns, highlights repositioning opportunities, characterizes single-cell heterogeneity, and proposes bispecific CST combinations to improve tumor specificity and reduce toxicity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-cell-surface-targets-in-metastatic-and-primary-solid-cancers/341960/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-cell-surface-targets-in-metastatic-and-primary-solid-cancers/341960.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of the study on cell-surface targets (CSTs)?","Question",{"text":113,"@type":114},"To map and define the clinical landscape of CST expression across metastatic and primary solid cancers using integrated datasets and clinical-trial information.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the authors compare RNA expression with protein expression for CSTs?",{"text":118,"@type":114},"They used matched RNA versus protein expression data and found that high RNA expression accurately predicted high protein expression across benign tissues, tumor samples, and cell lines.",{"name":120,"@type":111,"acceptedAnswer":121},"What additional analyses help evaluate toxicity and therapeutic specificity?",{"text":122,"@type":114},"Single-cell analyses identify rare normal cell subpopulations that may contribute to toxicity, and the study evaluates CST therapy combinations where bispecific approaches could improve tumor specificity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341960,1790190957,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","RESOUR CE  \nAND  \nTE CHNIC AL  \nADVANCE  \nAuthorship note: MNS andYS contributed equally to this work.  \nConflict of interest: SGZ has patent applications with Veracyte on molecular signatures in prostate cancer unrelated to this work, and a family member employed by Artera, and with stock in Exact Sciences. MLB has a family member employed by Luminex – A DiaSorin Company. FYF reports personal fees from Janssen Oncology, Bayer, PFS Genomics, Myovant Sciences, Roivant Sciences, Astellas Pharma, Foundation Medicine, Varian, Bristol Myers Squibb (BMS), Exact Sciences, BlueStar Genomics, Novartis, and Tempus; other support from Serimmune and Artera outside the submitted work. VTM is a consultant/advisory board member for Immunocore, Regeneron Pharmaceuticals, Incyte, Replimune, Partner Therapeutics, and BMB. MS reports speaker fees from Astellas, Scientific Advisory board for Veracyte/ Adelphi Targis. YS reports employment at Tempus with restricted stock units. MNS reports other support from Novartis unrelated to the submitted work.  \nCopyright: © 2024, Sharifi et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: June 6, 2024  \nAccepted: July 31, 2024  \nPublished: September 24, 2024  \nReference information: JCI Insight. 2024;9(18):e183674 .  \n[https://doi.org/10.1172/jci](https://doi.org/10.1172/jci). insight.183674 .  \nClinical cell-surface targets in metastatic and primary solid cancers  \nMarina N. Sharifi,1,2 Yue Shi,3 Matthew R. Chrostek,3 S. Carson Callahan,3 Tianfu Shang,3 Tracy J. Berg,3 Kyle T. Helzer,3 Matthew L. Bootsma,3 Martin Sjöström,4,5 Andreas Josefsson,6 Felix Y. Feng,7 Laura B. Huffman,8 Chris Schulte,3 Grace C. Blitzer,2,3 Quaovi H. Sodji,2,3 Zachary S. Morris,2,3 Vincent T. Ma,1,2 Labros Meimetis,2,9 David Kosoff,1,2,10 Amy K. Taylor,1,2 Aaron M. LeBeau,2,9,11 Joshua M. Lang,1,2 and Shuang G. Zhao2,3  \n1Department of Medicine, 2Carbone Cancer Center, and 3Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, USA. 4Department of Clinical Sciences Lund, Division of Oncology, Lund University, Lund, Sweden. 5Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. 6Wallenberg Center for Molecular Medicine, Urology, Department of Diagnostics and Intervention, Umeå University, Umea, Sweden. 7Departments of Radiation Oncology, Urology, and Medicine, UCSF, San Francisco, California, USA. 8Department of Obstetrics and Gynecology and 9Department of Radiology, University of Wisconsin, Madison, Wisconsin, USA. 10William S. Middleton Memorial Veterans’ Hospital, Madison, Wisconsin, USA. 11Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.  \nTherapies against cell-surface targets (CSTs) represent an emerging treatment class in solid malignancies. However, high-throughput investigations of CST expression across cancer types have been reliant on data sets of mostly primary tumors, despite therapeutic use most commonly in metastatic disease. We identified a total of 818 clinical trials of CST therapies with 78 CSTs. We assembled a data set spanning RNA-seq and microarrays in 7,927 benign samples, 16,866 primary tumor samples, and 6,124 metastatic tumor samples. We also utilized single-cell RNA-seq data from 36 benign tissues and 558 primary and metastatic tumor samples, and matched RNA versus protein expression in 29 benign tissue samples, 1,075 tumor samples, and 942 cell lines. High RNA expression accurately predicted high protein expression across CST therapies in benign tissues, tumor samples, and cell lines. We compared metastatic versus primary tumor expression, identified potential opportunities for repositioning, and matched cell lines to tumor types based on CST and global RNA expression. We evaluated single-cell heterogeneity across tumors, and identified rare normal cell subpopulations that may contribute to toxicity. Fina","cbCaidBEbIHJN7Va","https://ap.wps.com/l/cbCaidBEbIHJN7Va","pdf",18181598,16,"English","# Introduction\n## Overview of cell-surface-targeted therapies and classes","[{\"question\":\"What is the main goal of the study on cell-surface targets (CSTs)?\",\"answer\":\"To map and define the clinical landscape of CST expression across metastatic and primary solid cancers using integrated datasets and clinical-trial information.\"},{\"question\":\"How did the authors compare RNA expression with protein expression for CSTs?\",\"answer\":\"They used matched RNA versus protein expression data and found that high RNA expression accurately predicted high protein expression across benign tissues, tumor samples, and cell lines.\"},{\"question\":\"What additional analyses help evaluate toxicity and therapeutic specificity?\",\"answer\":\"Single-cell analyses identify rare normal cell subpopulations that may contribute to toxicity, and the study evaluates CST therapy combinations where bispecific approaches could improve tumor specificity.\"}]","Clinical cell-surface targets in metastatic and primary solid cancers | PDF",1790044518,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6615a9f148ca52116888c31aa3f49c31.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2aa46750652884c31ffd845ac3018dda.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4dbf9b7437620b72decaa8c12ff6b0c.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8684d8c962564c744bd7c0c5186cbd66.webp",980,1311]